Incretin-based therapy: renal effects
Glucagon like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors are new classes of hypoglycemic agents with numerous pleiotropic effects. The review summarises data about the influence of GLP-1 analogues and DPP-4 inhibitors on structural and functional changes in diabetic ki...
Guardado en:
Autores principales: | Anton Ivanovich Korbut, Vadim Valerievich Klimontov |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5c2fe686f9b64d1a9647f4b4cad14b69 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The associations of incretin hormone concentration with gestational diabetes mellitus
por: Tatiana V. Saprina, et al.
Publicado: (2016) -
The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future
por: Juris J. Meier
Publicado: (2019) -
Incretins today: multiple effects and therapeutic potential
por: Oksana V. Tsygankova, et al.
Publicado: (2019) -
New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.
por: Ekaterina Alekseevna Shestakova
Publicado: (2011) -
Pharmalogical effects and results of clinical trials of the first incretinomimetic exenatide
por: Alexander Sergeevich Ametov, et al.
Publicado: (2011)